Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HANSIZHUANG (serplulimab injection) in combination with chemotherapy for the treatment of early-stage gastric cancer met its primary endpoint of event-free survival. This significant finding supports an early new drug application submission, indicating a promising advancement in cancer treatment. The study demonstrated a notable improvement in the pathological complete response rate and a reduction in recurrence risk, with a favorable safety profile, enhancing the company’s position in the oncology market.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$79.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of innovative monoclonal antibodies. The company is involved in producing treatments for various cancers, including lung, esophageal, and gastric cancers, with a market presence in China and several international regions.
Average Trading Volume: 1,400,187
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.75B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.